[en] Background: Multimodal therapy for acromegaly affords adequate disease control for many patients; however, there remains a subset of individuals that exhibit treatment-resistant disease. The issue of treatment-resistant pituitary tumor growth remains relatively under-explored. Methods: We assessed the literature for relevant data regarding the surgical, medical and radio-therapeutic treatment of acromegaly in order to identify the factors that were predictive of aggressive or treatment-resistant pituitary tumor behavior in acromegaly and undertook an assessment of the rates of failure to control tumor progression with available treatment modalities. Results: Young age at diagnosis, large tumor size, high growth hormone secretion and certain histological markers are predictors of future aggressive tumor behavior in acromegaly. Significant tumor regrowth occurs in less than 10% of cases thought to be cured surgically, whereas failure to control tumor growth is seen in less than 1% of patients receiving radiotherapy. Somatostatin analogs induce a variable degree of tumor shrinkage in acromegaly but up to 2.2% of somatostatin analog-treated tumors continue to grow. Relative to other therapies, limited data are available for pegvisomant, but these indicate that persistent tumor growth occurs in 1.6-2.9% of cases followed up regularly with serial magnetic resonance imaging scans. Conclusions: Treatment-resistant tumor progression occurs in a small minority of patients with acromegaly, regardless of treatment modality. Young patients with large tumors or those with high pre-treatment levels of growth hormone particularly warrant close monitoring for continued tumor progression during treatment for acromegaly.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veidhuis J, Wass J, von Werder K & Melmed S. Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2000 85 526-529.
Lundin P, Eden Engstrom B, Karlsson FA & Burman P. Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR. American Journal of Neuroradiology 1997 18 765-772.
Salaun C, Foubert L, Vialatou M, Kujas M & Turpin G. Prognostic factors in the surgical management of acromegaly (in French). Annales Medicine Interne (Paris) 1999 150 195-198.
Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB & Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. Journal of Clinical Endocrinology and Metabolism 1998 83 3411-3418.
van der Lely AJ, Harris AG & Lamberts SW. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clinical Endocrinology 1992 37 181-185.
Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y & Kobayashi S. Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index. Journal of Neurosurgery 2003 98 359-365.
Nomikos P, Buchfelder M & Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. European Journal of Endocrinology 2005 152 379-387.
Ahmed S, Elsheikh M, Stratton IM, Page RC, Adams CB & Wass JA. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience. Clinical Endocrinology 1999 50 561-567.
Beauregard C, Truong U, Hardy J & Serri O. Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clinical Endocrinology 2003 58 86-91.
De P, Rees DA, Davies N, John R, Neal J, Mills RG, Vafidis J, Davies JS & Scanion MF. Transsphenoidal surgery for acromegaly in Wales: results based on stringent criteria of remission. Journal of Clinical Endocrinology and Metabolism 2003 88 3567-3572.
Kreutzer J, Vance ML, Lopes MB & Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. Journal of Clinical Endocrinology and Metabolism 2001 86 4072-4077.
Bando H, Sano T, Ohshima T, Zhang CY, Yamasaki R, Matsumoto K & Saito S. Differences in pathological findings and growth hormone responses in patients with growth hormone-producing pituitary adenoma. Endocrinology Japan 1992 39 355-363.
Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG & Kovacs K. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. European Journal of Endocrinology 1995 133 686-690.
Mazal PR, Czech T, Sedivy R, Aichholzer M, Wanschitz J, Klupp N & Budka H. Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of acromegalic patients. Clinical Neuropathology 2001 20 163-171.
Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Scucchi LF, Gulino A & Cantore G. A criticai reappraisal of MEB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocrine Related Cancer 2002 9 103-113.
Kitz K, Knosp E, Koos WT & Korn A. Proliferation in pituitary adenomas: measurement by MAb KI 67. Acta Neurochirurgica (Wien) 1991 53 (Suppl) 60-64.
Iuchi S, Saeki N, Uchino Y, Higuchi Y, Tatsuno I, Nakamura S, Yasuda T & Yamaura A. Cavernous sinus invasion and tumor proliferative potential of growth hormone-producing pituitary tumors. Endocrine Journal 2000 47 (Suppl) S77-S79.
Turner HE, Nagy Z, Esiri MM, Harris AL & Wass JA. Role of matrix metalloproteinase 9 in pituitary tumor behavior. Journal of Clinical Endocrinology and Metabolism 2000 85 2931-2935.
Turner HE, Harris AL, Melmed S & Wass JA. Angiogenesis in endocrine tumors. Endocrine Reviews 2003 24 600-632.
Turner HE, Nagy Z, Sullivan N, Esiri MM & Wass JA. Expression analysis of cyclins in pituitary adenomas and the normal pituitary gland. Clinical Endocrinology (Oxford) 2000 53 337-344.
Asa SL & Ezzat S. The pathogenesis of pituitary tumours. Nature Reviews Cancer 2002 2 836-849.
Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H, Enjalbert A & Jaquet P. Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas. Journal of Clinical Endocrinology and Metabolism 1998 83 1604-1610.
Ezzat S, Zheng L, Zhu XF, Wu GE & Asa SL. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. Journal of Clinical Investigation 2002 109 69-78.
Qian ZR, Sano T, Asa SL, Yamada S, Horiguchi H, Tashiro T, Li CC, Hirokawa M, Kovacs K & Ezzat S. Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. Journal of Clinical Endocrinology and Metabolism 2004 89 1904-1911.
Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B & Klibanski A. Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. Journal of Clinical Endocrinology and Metabolism 2002 87 1262-1267.
Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD & Melmed S. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1999 84 761-767.
Marx SJ & Nieman LK. Aggressive pituitary tumors in MEN1: do they refute the two-hit model of tumorigenesis? Journal of Clinical Endocrinology and Metabolism 2002 87 453-456.
Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe B, Montvernay C & Calender A. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. Journal of Clinical Endocrinology and Metabolism 2002 87 457-465.
Verloes A, Stevenaert A, Teh BT, Petrossians P & Beckers A. Familial acromegaly: case report and review of the literature. Pituitary 1999 1 273-277.
McCarthy MI, Noonan K, Wass JA & Monson JP. Familial acromegaly: studies in three families. Clinical Endocrinology (Oxford) 1990 32 719-728.
Stevenaert A & Beckers A. Presurgical octreotide: treatment in acromegaly. Metabolism 1996 45 72-74.
Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L & Kleinberg DL. Octreotide as primary therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 3034-3040.
Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner ME, Wass JAH & Wardlaw JM. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. Journal of Clinical Endocrinology and Metabolism 2002 87 4554-4563.
Clemmons DR, Chihara K, Freda PU, Ho KK, Klibanski A, Melmed S, Shalet SM, Strasburger CJ, Trainer PJ & Thorner MO. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. Journal of Clinical Endocrinology and Metabolism 2003 88 4759-4767.
AACE Medical Guidelines for Clinical Practice. The diagnosis and treatment of acromegaly. Endocrine Practice 2004 10 213-225.
Freda PU. Somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism 2002 87 3013-3018.
Bevan JS. The anti-tumoral effects of somatostatin analog therapy in Acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 1856-1863.
Giusti M, Ciccarelli E, Dallabonzana D, Delitala G, Faglia G, Liuzzi A, Gussoni G & Disem GG. Clinical results of long-term slow-release lanreotide treatment of acromegaly. European Journal of Clinical Investigation 1997 27 277-284.
Suliman M, Jenkins R, Ross R, Powell T, Battersby R & Cullen DR. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. Journal of Endocrinological Investigation 1999 22 409-418.
Tauber JP, Babin T, Tauber MT, Vigoni F, Bonafe A, Ducasse M, Harris AG & Bayard F. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism 1989 68 917-924.
Barakat S & Melmed S. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide. Archives of Internal Medicine 1989 149 1443-1445.
Arosio M, Macchelli S, Rossi CM, Casati G, Biella O & Faglia G. Effects of treatment with octreotide in acromegalic patients - a multicenter Italian study. Italian Multicenter Octreotide Study Group. European Journal of Endocrinology 1995 133 430-439.
Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Annals of Internal Medicine 1992 117 711-718.
Flogstad AK, Halse J, Haldorsen T, Lancranjan I, Marbach P, Bruns C & Jervell J. Sandostatin LAR in acromegalic patients: a dose-range study. Journal of Clinical Endocrinology and Metabolism 1995 80 3601-3607.
Stewart PM, Stewart SE, Clark PM & Sheppard MC. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clinical Endocrinology (Oxford) 1999 50 295-299.
Ezzat S, Horvath E, Harris AG & Kovacs K. Morphological effects of octreotide on growth hormone-producing pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1994 79 113-118.
Losa M, Ciccarelli E, Mortini P, Barzaghi R, Gaia D, Faccani G, Papotti M, Mangili F, Terreni MR, Camanni F & Giovanelli M. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 2001 86 5194-5200.
Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM & Scarlett JA. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 1171-1177.
Ho KK. Place of pegvisomant in acromegaly. Lancet 2001 358 1743-1744.
van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hacker S, Zib KA, Davis RJ, Scarlett JA & Thorner MO. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 358 1754-1759.
van der Lely AJ, Muller A, Janssen JA, Davis RJ, Zib KA, Scarlett JA & Lamberts SW. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. Journal of Clinical Endocrinology and Metabolism 2001 86 478-481.
Thorner MO, Chait A, Aitken M, Benker G, Bloom SR, Mortimer CH, Sanders P, Mason AS & Besser GM. Bromocriptine treatment of acromegaly. British Medical Journal 1975 1 299-303.
Besser GM & Wass JA. Medical management of acromegaly with bromocriptine. Effects of continuous treatment for over three years. Medical Journal of Australia 1978 2 31-33.
Jaffe CA & Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinology and Metabolism Clinics of North America 1992 21 713-735.
Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, Da Re N, Branca V, Oppizzi G & Gelli D. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? European Journal of Endocrinology 1998 139 516-521.
Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C & Beckers A. Cabergoline in the treatment of acromegaly: a study in 64 patients. Journal of Clinical Endocrinology and Metabolism 1998 83 374-378.
Muratori M, Arosio, M, Gambino G, Romano C, Biella O & Faglia G. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. Journal of Endocrinological Investigation 1997 20 537-546.
Oppizzi G, Liuzzi A, Chiodini P, Dallabonzana D, Spelta B, Silvestrini F, Borghi G & Tonon C. Dopaminergic treatment of acromegaly: different effects on hormone secretion and tumor size. Journal of Clinical Endocrinology and Metabolism 1984 58 988-992.
Eastman RC, Gorden P, Glatstein E & Roth J. Radiation therapy of acromegaly. Endocrinology and Metabolism Clinics of North America 1992 21 693-712.
Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF & Sandler HM. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 1997 82 3187-3191.
Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, von Werder K, Wass J & Giustina A. Guidelines for acromegaly management. Journal of Clinical Endocrinology and Metabolism 2002 87 4054-4058.
Izawa M, Hayashi M, Nakaya K, Satoh H, Ochiai T, Hori T & Takakura K. Gamma knife radiosurgery for pituitary adenomas. Journal of Neurosurgery 2000 93 (Suppl 3) 19-22.
Cozzi R, Barausse M, Asnaghi D, Dallabonzana D, Lodrini S & Attanasio R. Failure of radiotherapy in acromegaly. European Journal of Endocrinology 2001 145 717-726.
Lucas T, Astorga R & Catala M. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clinical Endocrinology (Oxford) 2003 58 471-481.
Abe T & Ludecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. European Journal of Endocrinology 2001 145 137-145.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.